Antisense oligonucleotides: modifications and clinical trials

Nucleic acid therapeutics: basic concepts and recent developments

(2014) Vivek K. Sharma et al.   RSC Advances

Effects of miR-155 Antisense Oligonucleotide on Breast Carcinoma Cell Line MDA-MB-157 and Implanted Tumors

(2013) Shu-Rong Zheng et al.   Asian Pacific Journal of Cancer Prevention

C3′-endo-puckered pyrrolidine containing PNA has favorable geometry for RNA binding: Novel ethano locked PNA (ethano-PNA)

(2013) Anjan Banerjee et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Locked nucleic acid: tighter is different

(2013) Jonathan K. Watts   CHEMICAL COMMUNICATIONS

Mipomersen Sodium: First Global Approval

(2013) Philip Hair et al.   DRUGS

Design and Synthesis of LNA-Based Mercaptoacetamido-Linked Nucleoside Dimers

(2013) Vivek K. Sharma et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Synthesis and Biophysical Properties of Constrained d-Altritol Nucleic Acids (cANA)

(2013) Michael T. Migawa et al.   ORGANIC LETTERS

Guideline of transthyretin-related hereditary amyloidosis for clinicians

(2013) Yukio Ando et al.   Orphanet Journal of Rare Diseases

Hybridizing ability and nuclease resistance profile of backbone modified cationic phosphorothioate oligonucleotides

(2012) S.M. Abdur Rahman et al.   BIOORGANIC & MEDICINAL CHEMISTRY

RNA-Based Therapeutics: Current Progress and Future Prospects

(2012) John C. Burnett et al.   CHEMISTRY & BIOLOGY

Emerging drugs for Duchenne muscular dystrophy

(2012) Vinod Malik et al.   EXPERT OPINION ON EMERGING DRUGS

Novel targeted therapies for eosinophilic disorders

(2012) Michael E. Wechsler et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Discovering the first microRNA-targeted drug

(2012) Morten Lindow et al.   JOURNAL OF CELL BIOLOGY

Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist

(2012) Zuzanna Makowska et al.   JOURNAL OF HEPATOLOGY

Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat

(2012) Claudia Carrieri et al.   NATURE

Phosphorothioate DNA as an antioxidant in bacteria

(2012) Xinqiang Xie et al.   NUCLEIC ACIDS RESEARCH

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

(2012) Mary P. McGowan et al.   PLoS One

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

(2012) Petra Jilma-Stohlawetz et al.   THROMBOSIS AND HAEMOSTASIS

Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey

(2012) Scott P. Henry et al.   TOXICOLOGY

Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections

(2012) Patrick Iversen et al.   Viruses-Basel

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals

(2012) Punit P Seth et al.   Molecular Therapy-Nucleic Acids

Delayed Graft Function in the Kidney Transplant

(2011) A. Siedlecki et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

(2011) Jorge Cortes et al.   CANCER

An Overview of Sugar-Modified Oligonucleotides for Antisense Therapeutics

(2011) Thazha P. Prakash   CHEMISTRY & BIODIVERSITY

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

(2011) D. S. Hong et al.   CLINICAL CANCER RESEARCH

The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2

(2011) Frank Jaschinski et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Efficacy of a Phosphorodiamidate Morpholino Oligomer Antisense Compound in the Inhibition of Corneal Transplant Rejection in a Rat Cornea Transplant Model

(2011) Alireza Hosseini et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Chemical Modification of siRNA Bases To Probe and Enhance RNA Interference

(2011) Hayden Peacock et al.   JOURNAL OF ORGANIC CHEMISTRY

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

(2011) Janessa J. Laskin et al.   Journal of Thoracic Oncology

The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia

(2011) J Dürig et al.   LEUKEMIA

OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer

(2011) V Baylot et al.   Cell Death & Disease

Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells

(2010) Ping Chen et al.   AAPS Journal

RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027

(2010) Peter K. Kaiser et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial

(2010) Paul G. Richardson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Effect of 3′-end capping of aptamer with various 2′,4′-bridged nucleotides: Enzymatic post-modification toward a practical use of polyclonal aptamers

(2010) Yuuya Kasahara et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Clinical status of duplex RNA

(2010) Jonathan K. Watts et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide

(2010) Sophie Callies et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase II Study of the Novel Peptide-Nucleic Acid OHR118 in the Management of Cancer-Related Anorexia/Cachexia

(2010) Martin Chasen et al.   Journal of the American Medical Directors Association

Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer

(2010) Panos Fidias et al.   Journal of Thoracic Oncology

Aptamers as therapeutics

(2010) Anthony D. Keefe et al.   NATURE REVIEWS DRUG DISCOVERY

Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide

(2010) Puja Sapra et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

(2009) R. Plummer et al.   CLINICAL CANCER RESEARCH

GS-101 Antisense Oligonucleotide Eye Drops Inhibit Corneal Neovascularization

(2009) Claus Cursiefen et al.   OPHTHALMOLOGY

COMBINATION THERAPY USING THE SMALL INTERFERING RNA BEVASIRANIB

(2009) LAWRENCE SINGERMAN   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Antisense Treatment for Myasthenia Gravis

(2008) Jon D. Sussman et al.   Annals of the New York Academy of Sciences

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)

(2008) J DEVINCENZO et al.   ANTIVIRAL RESEARCH

Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer

(2008) A. I. So et al.   CLINICAL CANCER RESEARCH

A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth

(2008) L. M. Greenberger et al.   MOLECULAR CANCER THERAPEUTICS

Triazole-Linked Analogue of Deoxyribonucleic Acid (TLDNA): Design, Synthesis, and Double-Strand Formation with Natural DNA

(2008) Hiroyuki Isobe et al.   ORGANIC LETTERS

c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model

(2007) Harmanjatinder S. Sekhon et al.   LUNG CANCER